{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:08:47Z","timestamp":1780088927963,"version":"3.54.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jclinepi.2026.112227","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:31:17Z","timestamp":1773826277000},"page":"112227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-3940","authenticated-orcid":false,"given":"Fran","family":"\u0160aler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-2379","authenticated-orcid":false,"given":"Ivan","family":"Paladin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6606-8937","authenticated-orcid":false,"given":"Ivana","family":"Bla\u017eekovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Boras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0037-4905","authenticated-orcid":false,"given":"Ru\u017eica","family":"Tokali\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-9598","authenticated-orcid":false,"given":"Marin","family":"Vi\u0111ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Puljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jclinepi.2026.112227_bib1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key concepts of clinical trials: a narrative review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jclinepi.2026.112227_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40900-018-0118-y","article-title":"Engaging knowledge users in development of the CONSORT-equity 2017 reporting guideline: a qualitative study using in-depth interviews","volume":"4","author":"Jull","year":"2018","journal-title":"Res Involv Engagem"},{"issue":"10","key":"10.1016\/j.jclinepi.2026.112227_bib3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jama.1990.03440100097014","article-title":"The existence of publication bias and risk factors for its occurrence","volume":"263","author":"Dickersin","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112227_bib4","article-title":"Full publication of results initially presented in abstracts","volume":"11","author":"Scherer","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112227_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066844","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review","volume":"8","author":"Dwan","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s13063-021-05790-9","article-title":"Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA","volume":"22","author":"Swanson","year":"2021","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes Publ Am Diabetes Assoc"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112227_bib9","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jclinepi.2026.112227_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111685","article-title":"Heterogeneity across outcomes in clinical trials on sodium-glucose cotransporter 2 inhibitors in chronic heart failure: a cross-sectional study","volume":"180","author":"\u0160aler","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2026.112227_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12874-024-02292-5","article-title":"Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study","volume":"24","author":"\u0160aler","year":"2024","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112227_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112227_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jclinepi.2026.112227_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003436","article-title":"Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension","volume":"3","author":"Hodkinson","year":"2013","journal-title":"BMJ Open"},{"issue":"7626","key":"10.1016\/j.jclinepi.2026.112227_bib17","first-page":"0","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12874-022-01730-6","article-title":"Reporting of the safety from allergic rhinitis trials registered on ClinicalTrials.gov and in publications: an observational study","volume":"22","author":"Paladin","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12874-025-02486-5","article-title":"Discrepancies in safety reporting for chronic back pain clinical trials: an observational study from ClinicalTrials.gov and publications","volume":"25","author":"Boyne","year":"2025","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79394-z","article-title":"Safety reporting in trials on glaucoma interventions registered in ClinicalTrials.gov and corresponding publications","volume":"14","author":"Kre\u0161o","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12874-018-0627-2","article-title":"Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology","volume":"18","author":"Serpas","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112227_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/M13-0480","article-title":"Reporting discrepancies between the ClinicalTrials.gov results database and peer reviewed publications","volume":"160","author":"Hartung","year":"2014","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12916-015-0520-3","article-title":"Comparison of registered and published outcomes in randomized controlled trials: a systematic review","volume":"13","author":"Jones","year":"2015","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112227_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005535","article-title":"Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study","volume":"4","author":"Hughes","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112227_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001666","article-title":"Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials","volume":"11","author":"Dwan","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2026.112227_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112227_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085250","article-title":"An analysis of controlled human infection studies registered on ClinicalTrials.gov","volume":"15","author":"Toomey","year":"2025","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112227_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1185\/03007995.2013.860371","article-title":"Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe","volume":"30","author":"Rawal","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.jclinepi.2026.112227_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009758","article-title":"Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012","volume":"5","author":"Miller","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jclinepi.2026.112227_bib30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/dom.14286","article-title":"Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: a meta-analysis of randomized controlled trials","volume":"23","author":"Silverii","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112227_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03272.x","article-title":"Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?","volume":"66","author":"Golder","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"31","key":"10.1016\/j.jclinepi.2026.112227_bib32","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2015.62.4148","article-title":"From protocols to publications: a study in selective reporting of outcomes in randomized trials in oncology","volume":"33","author":"Raghav","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s13063-019-3592-0","article-title":"An analysis of deficiencies in the data of interventional drug trials registered with Clinical Trials Registry - India","volume":"20","author":"Pillamarapu","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112227_bib34","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1186\/s13063-022-06569-2","article-title":"Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000\u20132020","volume":"23","author":"Gresham","year":"2022","journal-title":"Trials"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626001022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626001022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:35:43Z","timestamp":1780086943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626001022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0895435626001022"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112227","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reporting of sodium-glucose cotransporter 2 (SGLT2) inhibitor trial safety: an observational analysis of ClinicalTrials.gov registrations and journal publications","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112227"}}